The American Journal of Managed Care

Managed Care Considerations in the Treatment of Demodex Blepharitis

AJMC®: Could you describe the current standard of care for Demodex blepharitis and how it has evolved? PERIMAN: The understanding and management of Demodex blepharitis have evolved quite a bit in ...
Action Reporter Media

FDA-Approved Drop XDEMVY Offers Targeted Relief for Demodex Blepharitis Patients, Modern Vision Solutions Reports

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Ophthalmology Times

NMPA approves lotilaner ophthalmic solution for demodex blepharitis in China

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...
The American Journal of Managed Care

Interview with Laura M. Periman, MD: Managed Care Considerations in the Treatment of Demodex Blepharitis

The standard of care for Demodex blepharitis has improved substantially. The current approach involves both identifying and treating the condition effectively. Patients with Demodex blepharitis may ...

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye ...
Yahoo Finance

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE)-- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory ...